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A B S T R A C T
Apart from osteogenesis, neovascularization of the defect area is an important determinant for successful bone
healing. Accordingly, several studies have employed the combined delivery of VEGFA and BMP2 for bone re-
generation. Nevertheless, the outcomes of these studies are highly variable. The aim of our study was to compare
the effectiveness of adenoviral mediated delivery of BMP2 alone and in combination with VEGFA in rat bone
marrow stromal cells (rBMSC) seeded on a poly(LLA-co-CL) scaffold in angiogenesis and osteogenesis using a
critical-sized rat calvarial defect model. Both mono delivery of BMP2 and the combined delivery of a lower ratio
of VEGFA and BMP2 (1:4) led to up-regulation of osteogenic genes (Alpl and Runx2) and increased calcium
deposition in vitro, compared with the GFP control. Micro computed tomography (microCT) analysis of the rat
calvarial defect at 8 weeks showed that the mono delivery of BMP2 (43.37± 3.55% defect closure) was the most
effective in healing the bone defect, followed by the combined delivery of BMP2 and VEGFA (27.86±2.89%)
and other controls. Histological and molecular analyses supported the microCT findings. Analysis of the an-
giogenesis, however, showed that both mono delivery of BMP2 and combined delivery of BMP2 and VEGFA had
similar angiogenic effect in the calvarial defects. Examination of the key genes related to host response against
the adenoviral vectors showed that the current model system was not associated with adverse immune response.
Overall, the results show that the mono delivery of BMP2 was superior to the combined delivery of BMP2 and
VEGFA in healing the critical-sized rat calvarial bone defect. These findings underscore the importance of ap-
propriate growth factor combination for the successful outcome in bone regeneration.
1. Introduction
The autologous bone graft, although considered the gold standard
for the treatment of large bone defects, is unable to meet the current
increased need for bone grafting (Fillingham and Jacobs, 2016).
Moreover, the procedure has a number of drawbacks, such as donor site
morbidity, leading to prolonged hospital admissions and higher asso-
ciated costs, unpredictable healing and resorption (Fillingham and
Jacobs, 2016; Younger and Chapman, 1989). In this context, bone
tissue engineering (BTE) approach is rapidly evolving as a promising
alternative to the autologous bone grafting procedures. For successful
outcome in BTE, selection of appropriate osteoinductive and/or an-
giogenic growth factors, a suitable delivery method and a proper
supportive scaffold are critical. Additionally angiogenesis is cruical for
the survival and the integration of BTE construct and effective bone
healing. In an attempt to dev elop an effective model system for BTE,
we previously investigated adenoviral-mediated delivery of bone mor-
phogenetic protein 2 (BMP2) and vascular endothelial growth factor A
(VEGFA) alone or in combination in human bone marrow stromal cells
(BMSC) seeded onto a biodegradable and well characterized copolymer
poly(L-lactide-co-ϵ-caprolactone) (poly(LLA-co-CL)) scaffold (Sharma
et al., 2016). The careful selection of poly(LLA-co-CL) scaffold for this
model system was based on our previous findings, that this scaffolding
material has optimal biophysical features (Dånmark et al., 2011;
Odelius et al., 2005), such as surface characteristics and biocompat-
ibility (Xue et al., 2010; Xing et al., 2011; Idris et al., 2010) for BTE.
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Additionally, the adenoviral mediated gene delivery method used in
this model minimizes the disadvantages (such as rapid degradation,
requirement of supraphysiological doses and unpredictable adverse
effects, and high cost) associated with the bulk delivery of recombinant
growth factors at the defect site (Evans, 2012).
In a previous study using a subcutaneous mouse model (ectopic)
system, we showed that adenoviral-mediated delivery of BMP2 in BMSC
seeded onto poly(LLA-co-CL) scaffolds was feasible and effective in
angiogenesis and bone regeneration (Sharma et al., 2016). Further, we
demonstrated that although BMSC expressing VEGFA alone, or in
combination with BMP2 significantly induced angiogenesis, VEGFA
alone failed to demonstrate osteogenic activity both in vitro and in vivo
in a subcutaneous mouse model as compared to the combined delivery
group (Sharma et al., 2018). Even in the combined delivery group, the
VEGFA appears not to provide any additional effect over the BMP2 in
bone regeneration (Sharma et al., 2016; Sharma et al., 2018). These
findings prompted us to exclude the delivery of VEGFA alone in the
current study. The current study aimed to examine and translate the
findings of our previous work in a more clinically relevant critical-sized
rat calvarial bone defect model and to compare the role of BMP2 alone
and in combination with VEGFA (VEGFA:BMP2=1:4) in angiogenesis
and in bone formation, at both molecular and functional levels.
2. Materials and methods
2.1. Rat BMSC (rBMSC) isolation and culture
rBMSCs were isolated from 6-week old male Lewis rats as previously
described (Xing et al., 2011; Maniatopoulos et al., 1988). Briefly, after
1 week of acclimatization, four animals were euthanized by carbon
dioxide (CO2) inhalation and cervical dislocation. The femurs were
removed and carefully scrubbed to remove soft tissues and washed with
phosphate buffered saline (PBS) supplemented with 3% antibiotic-an-
timycotic (Gibco, Life technologies). The metaphyseal ends of the fe-
murs were excised and the marrow cavity was flushed with complete
minimum essential medium (αMEM, Invitrogen, Carlsbad, California,
USA) to collect the bone marrow cells into a sterile falcon tube. The
isolated cells were centrifuged and suspended in fresh α-MEM medium
containing 1% penicillin-streptomycin, 15% FBS and 1% glutamax, and
plated in culture flasks. The following day, unattached cells were dis-
carded and the medium was replaced with fresh αMEM medium con-
taining 1% glutamax, 1% penicillin-streptomycin and 10% FBS. The
cells were sub-cultured at day 3 when they appeared spindle-shaped
and had reached 80–90% confluence. The Norwegian Animal Research
Authority approved the animal experiment (local approval number
20146703) and all animal experiments were conducted in accordance
to the European Convention for the Protection of Vertebrates.
2.2. Preparation of rBMSC seeded scaffolds
Porous poly(LLA-co-CL) scaffolds were fabricated using the solvent-
casting particulate-leaching method as described previously (Odelius
et al., 2005; Danmark et al., 2010). For in vitro experiments, scaffolds
(diameter≈ 12mm, height≈ 1.3mm, porosity: 85% and average pore
size: 90–500 μm as determined by microcomputed tomography) were
placed on the bottom of 48-well plates, pre-wetted with the culture
medium and incubated overnight at a humidified atmosphere at 37 °C
and 5% CO2. rBMSC were seeded at a density of 1×105 cells/scaffold.
2.3. Adenoviral expression vector construction and transduction of rBMSC
In the current study, we used adenoviral mediated expression con-
structs for human BMP2 and VEGFA as previously used in our studies
(Sharma et al., 2016; Sharma et al., 2018). A high level of sequence
homology has been reported between human and rat BMP2 (Freire
et al., 2012; Freire et al., 2015) and VEGFA (Avivi et al., 1999; Ferrara,
2002) proteins, and accordingly in many studies human recombinant
BMP2 and VEGFA have been used successfully in bone regeneration
experiments in the rat (Park et al., 2003; Li et al., 2016). Replication-
deficient adenoviral expression vectors carrying the coding sequences
of VEGF165 (reference sequence: NM_001025370.2) (ad-VEGFA) and
BMP2 gene (reference sequence: NM_001200.2) (ad-BMP2) were pur-
chased from Cyagen Biosciences Inc. In the ad-VEGFA, gene encoding
for DsRed was used as a marker, and in the ad-BMP2 construct, gene
encoding for enhanced green fluorescent protein (eGFP) was used. The
adenoviral vector carrying only eGFP coding sequences (ad-GFP) was
used as a control. Adenoviral particles were generated by transfecting
HEK 293 cells (ATCC-CRL-1573) with Pac I digested constructs. Early
passage (passage 2–3) BMSC were infected as monolayer cultures with
respective adenoviruses (multiplicity of infection, MOI= 100) to ob-
tain 80–90% infection efficiency as disclosed by fluorescent micro-
scopy. Rat BMSC were infected with ad-GFP, ad-BMP2 and a mixture of
ad-VEGFA+BMP2 (20 MOI VEGFA+80 MOI BMP2; ratio 1:4) and
are henceforth be referred to as ‘ad-GFP’, ‘ad-BMP2’ and ‘ad-
BMP2+VEGFA’ respectively. After 48 h of infection in monolayer
culture with the respective adenoviral particles, rBMSC were seeded
onto poly(LLA-co-CL) scaffolds. rBMSC grown in scaffolds and the re-
spective conditioned media were harvested after 3 and 14 days for
mRNA analyses and ELISA assay respectively.
2.4. Total RNA extraction
Total RNA from the in vitro seeded scaffolds and the in vivo calvarial
explants were extracted using Maxwell® 16 LEV simplyRNA Kit (Cat no:
AS1270, Promega) on a Maxwell® 16 instrument following the manu-
facturer's protocol. The quantity and purity of total RNA were de-
termined using a Nanodrop Spectrophotometer (ThermoScientific Nano
Drop Technologies, Wilmington, DE, USA). The integrity of RNA was
examined by using Agilent 2100 Bioanalyzer (Agilent Technologies).
2.5. Reverse transcription and quantitative RT-PCR (qRT-PCR) using
TaqMan assays
Three hundred nanograms of total RNA were converted to cDNA by
reverse transcription reaction using a high capacity cDNA Archive Kit
(Applied Biosystems, Carlsbad, CA, USA). VEGFA (Hs00900055_m1)
and BMP2 (Hs00154192_m). TaqMan assays were used to verify the
expression of human VEGFA and BMP2mRNA in adenovirus transduced
rBMSC. The following TaqMan assays were used to amplify mRNAs
from rBMSC seeded onto scaffolds (in vitro) or rat calvarial explants in
vivo: Bmp2 (Rn00567818_m1), Vegfa (Rn01511601_m1), Alpl
(Rn01516028_m1), Runx2 (Rn01512298_m1), Spp1 (Rn00681031_m1),
Ostf1 (Rn00686607_m1), Ifna1 (Rn02395770_g1), Infb1
(Rn00569434_s1), Il1a (Rn00566700_m1) and Il1b (Rn00580432_m1).
Gapdh (Rn01749022_g1) was used as an endogenous control. All qRT-
PCR amplifications were performed on ABI Prism Sequence Detector
7900 HT (Applied Biosystems, Foster City, USA) under standard cycling
conditions. Comparative 2−ΔΔCt method was used to quantify the re-
lative mRNA expression.
2.6. Alkaline phosphatase (ALP) staining
ALP staining was used to analyze the osteoblastic differentiation
potential of rBMSC transduced with the respective adenoviral particles.
After 48 h of infection, cells were trypsinized and 2× 104 cells were
seeded in monolayers on 4-well culture dishes. ALP staining was done
on day 3 and 14. Briefly, cells were washed with PBS, fixed and stained
for ALP activity using SigmaFast™ BCIP/NBT (Sigma-Aldrich). The
staining intensity of captured images was quantified using ImageJ
software (1.5 versions for mac) using 8 bit gray scale images. The assay
was repeated at least three times.
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2.7. Alizarin red staining (in vitro mineralization assay)
To assess in vitro mineralization, Alizarin red staining was per-
formed on rBMSC from different experimental groups cultured as
monolayers as well as in poly(LLA-co-CL) scaffolds on day 21. Briefly,
after carefully washing with the Dulbecco's PBS, the cells grown in
monolayer culture and in scaffolds were fixed with 4% paraformalde-
hyde for 10min. Thereafter, the cells were stained with 2% Alizarin red
S staining solution (Sigma-Aldrich), incubated for 45min, washed, vi-
sualized and imaged under a light microscope.
2.8. Rat BMP2 ELISA
Culture supernatants from the transduced rat BMSC seeded onto
scaffolds were collected at 3 and 14 days for ELISA analysis of rat BMP2
(Cat no: KA0541, Abnova). ELISA assay was performed in duplicates
following the manufacturer's instructions.
2.9. In vivo critical-sized calvarial bone defect model in Lewis rat
2.9.1. Preparation of scaffold implants
Poly(LLA-co-CL) scaffolds (diameter≈ 5mm, height≈ 1.3mm,
porosity: 85% and average pore size: 90–500 μm as determined by
microcomputed tomography) were placed on the bottom of 96-well
plates, pre-wetted with the culture medium and incubated overnight at
a humidified atmosphere of 37 °C and 5% CO2. After 48 h of infection in
monolayer culture with the respective adenoviral particles, 1× 106 rat
BMSC were seeded onto each scaffold. To facilitate uniform cell dis-
tribution from the scaffold surface into the internal pores, culture plates
were gently shaken on an orbital shaker (Eppendorf, Germany) at
500 rpm for 5min. The scaffolds seeded with cells were incubated for a
further 3 h to allow cell attachment, and thereafter implanted into the
calvarial bone defects in Lewis rats. Scaffolds without any rBMSC
(scaffold only) were used as negative controls in the in vivo experi-
ments.
2.9.2. Surgical implantation of scaffolds
Thirty-four male Lewis rats (12 weeks old) (17 rats each for the 2
and 8week time-points) were used for scaffold implantation in the
calvarial defect. The animals were anesthetized with sevoflurane
(SevoFlo, Aesica Queenborough Limited, United Kingdom) in combi-
nation with air and O2. A surgical site extending from the bridge of the
snout between the eyes to the caudal end of the calvarium was prepared
by shaving the hair and scrubbing with the alcohol. An approximately
2 cm long midline sagittal incision was made, the periosteum covering
the calvarium was divided by an incision down the sagittal midline, and
the periosteum was gently pushed laterally while elevating it from the
underlying skull using an elevator. A saline-cooled trephine drill was
used to create two defects of 5mm diameter in each parietal bone,
carefully protecting the dura mater. The defects were randomly filled
with scaffolds containing one of the following groups of rBMSC (8 re-
plicates for each group for both 2 and 8week time-points): i) ad-GFP, ii)
ad-BMP2, iii) ad-BMP2+VEGFA or iv) untransduced. Scaffolds
without any cells (scaffold only group) were used as negative controls.
The incisions were closed with 4–0 vicryl sutures. The animals were
given a subcutaneous analgesic dose of Buprenorphine (Temgesic
0.3 mg/kg). The animals were monitored daily for condition of the
surgical wound, animal activity, food intake, and any signs of infection.
Animals were euthanized with CO2 inhalation and subsequent cervical
dislocation at 2 and 8weeks. Five of the scaffolds from each experi-
mental group at 2 week time point were cut into two halves and used
for i) RNA extraction (stored in RNA later, Ambion), and ii) cryosection
(embedded in Tissue-Tek). The remaining 3 scaffolds from each group
were fixed in 4% buffered formalin for 24 h, scanned using micro
computed tomography (microCT), decalcified in 12.5% EDTA and 2.5%
PFA in phosphate buffered saline for 7–10 days, and embedded in
paraffin. At 8 weeks, all of the scaffolds from each group were formalin
fixed, scanned using microCT, decalcified and embedded in paraffin for
histological analysis.
2.10. Histological analysis
The formalin fixed and paraffin embedded specimens were cut into
5 μm sections. The sections were deparaffinized in xylene, rehydrated in
graded ethanol and stained with Hematoxylin and Eosin or Masson's
trichrome stain. Vascularity in the implanted scaffolds was quantified in
Masson's trichrome stained slides by counting the pink/red stained
capillaries/blood vessels containing brown/orange stained ery-
throcytes. Briefly, at least three randomly selected areas per slide in-
cluding the periphery and interior of the scaffold explants were used to
count the capillaries/blood vessels using digitally scanned slides (20×;
Nano Zoomer XR digital scanner, Hamamatsu).
2.11. Micro computed tomography analysis (microCT)
The in vivo scaffold explants harvested at 2 and 8weeks were
scanned with a Sky Scan 1172 X-ray μCT imaging system (Kontich,
Belgium) to visualize the 3D distribution and volume of mineralized
tissue. Samples were scanned with an X-ray source of 60 kV/200 μA, a
0.5 mm aluminum filter for a 10 μm resolution, and a 0.4° rotation step.
The projection image was reconstructed using NRecon
ReconstructionVR (v. 1.6.10) software. The quantitative analysis of the
image was performed by CTan software (v.1.15, Skyscan, Belgium). A
global threshold of 90–255 was applied to all the samples after de-
termining the standardized cylindrical Volume of Interest (VOI), 5 mm
in diameter and 1.3 mm in height. Data were reported as the percentage
binarized object volume measured within this VOI. Bone volume (BV),
tissue volume (TV), and BV/TV ratios were recorded.
2.12. Statistical analyses
Data are expressed as mean± standard error of the mean (SEM).
ANOVA test with Bonferroni post hoc analysis was used for comparison
of the means between multiple groups. Statistical analyses were per-
formed using GraphPad Prism software version 5.00 for Windows
(GraphPad Software, San Diego California USA, www.graphpad.com),
with the level of significance set at 5%.
3. Results
3.1. BMP2 and VEGFA adenoviral expression vectors up-regulated
respective human and rat specific mRNAs in rBMSC
ad-BMP2 and ad-BMP2+VEGFA rBMSC seeded in poly(LLA-co-CL)
scaffolds expressed significantly higher levels of human BMP2 mRNA
level at days 3 and 14, compared with the control ad-GFP rBMSC
(Fig. 1A and E). Similarly, significantly higher levels of human VEGFA
mRNA were found in ad-VEGFA+BMP2 group at day 3 and 14,
compared with the control ad-GFP and ad-BMP2 groups (Fig. 1B and F).
It should be noted that expression of BMP2 mRNA was lower in ad-
BMP2+VEGFA group than in the ad-BMP2 group (Fig. 1A and E). We
next examined whether ad-BMP2 and ad-VEGFA constructs had any
influence on the expression of endogenous rat Bmp2 and Vegfa mRNA
levels in the rBMSC. Indeed, ad-BMP2 and ad-VEGFA constructs re-
spectively led to increased expression of rat Bmp2 and Vegfa mRNA and
secreted rat BMP2 protein both at day 3 and day 14 (Fig. 1C, D and
G–J). However, the BMP2 and VEGFA adenoviral vector mediated in-
duction of rat Bmp2 and Vegfa mRNA levels were not as pronounced as
that of the corresponding human mRNAs (Fig. 1A–H).
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Fig. 1. VEGFA and BMP2 adenoviral expression vectors respectively increased expression of both human and rat specific mRNA levels in rBMSC.
Significant up-regulation of human and rat specific BMP2 mRNA (A, C, E and G) and secreted BMP2 protein (I and J) levels were found at day 3 and 14 in both ad-
BMP2 and ad-BMP2+ ad-VEGFA groups, compared with the ad-GFP group. Similarly, significant up-regulation of human and rat specific VEGFA mRNA (B, D, F and
H) was found in ad-BMP2+VEGFA group, compared with the ad-GFP and ad-BMP2 groups at both time points. mRNA expression levels of Gapdh were used to
normalize the data. (I and J) Higher levels of secreted rat specific BMP2 protein were found in the culture supernatant of ad-BMP2 and ad-BMP2+VEGFA groups by
using ELISA assay at 3 and 14 days. The error bars in (A–H) represent SEM of 3 biological replicates (n=3) done in 3 technical replicates. The error bars in (I–J)
represent SEM of 3 biological replicates (n=3) done in duplicates. ANOVA test with Bonferroni post hoc analysis was used for statistical analysis in (A–J). ***,
p<0.001; **, p=0.001–0.01; *, p=0.01–0.05; ns, non-significant.
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3.2. Adenoviral mediated delivery of BMP2 alone and in combination with
VEGFA was associated with up-regulation of rat specific osteogenic markers
and increased calcification in vitro
Ad-BMP2 and ad-BMP2+VEGFA rBMSC seeded onto poly(LLA-co-
CL) scaffolds expressed significantly higher levels of Alpl and Runx2,
compared with the ad-GFP rBMSC both at 3 and 14 days (Fig. 2A–D). In
parallel, ALP activity significantly increased at 3 and 14 days in both
ad-BMP2 and ad-BMP2+VEGFA groups, compared with the ad-GFP
control group (Fig. 2E–G). These molecular changes were paralleled
functionally as demonstrated by the Alizarin red staining (Fig. 2H),
where significantly more calcium deposition was observed in ad-BMP2
and ad-BMP2+VEGFA rBMSC grown in monolayer and in poly(LLA-
co-CL) scaffolds, compared with the ad-GFP rBMSC. However, the
Fig. 2. Adenoviral vector mediated expression of BMP2 alone and in combination with VEGFA led to up-regulation of osteogenic molecules in vitro.
Significantly higher mRNA levels of Alpl and Runx2 were found in ad-BMP2 and ad-BMP2+VEGFA groups at both time points (A–D). The error bars represent SEM
of 3 biological replicates (n=3) done in 3 technical replicates. (E) Representative images and quantification (F and G) demonstrating higher alkaline phosphatase
activity in ad-BMP2 and ad-BMP2+VEGFA groups in monolayer culture, compared with the ad-GFP group at 3 and 14 days. Experiments were repeated at least
three times. ANOVA test with Bonferroni post hoc analysis was performed for statistical analysis in A–D, F and G. ***, p<0.001; **, p=0.001–0.01; *,
p=0.01–0.05; ns, non-significant. (H) Significantly higher amount of calcium deposition was found in ad-BMP2 and ad-BMP2+VEGFA groups both in monolayer
culture and in poly(LLA-co-CL) scaffold, compared with the ad-GFP group on 21 days. rBMSC grown in osteogenic medium was used as a positive control. The
experiments were repeated at least three times.
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intensity of Alizarin staining was weaker in ad-BMP2+VEGFA group
as compared to the ad-BMP2 group (Fig. 2H) which parallels with
slightly but significantly lower mRNA levels of Alpl and Runx2 in ad-
BMP2+VEGFA group (Fig. 2A–D).
3.3. Adenoviral mediated delivery of BMP2 alone was superior to the
combined delivery of BMP2+VEGFA in de novo bone formation and
healing of a critical sized rat calvarial defect
The ability of BMP2 alone or in combination with VEGFA to induce
de novo bone formation and healing was investigated by implanting
poly(LLA-co-CL) scaffold seeded with ad-BMP2, ad-BMP2+VEGFA,
ad-GFP or untransduced rBMSC in critical-sized bone defects in rat
calvaria. MicroCT analysis at 8 weeks revealed minimal healing of the
defect with few radiopaque bone like structures mostly at the periphery
of the defect from untransduced (n=8) and ad-GFP (n=8) explants
(Fig. 3C and D). In contrast, all analyzed replicates (n=8) from ad-
BMP2 and ad-BMP2+VEGFA scaffold explants revealed formation of
significant amounts of dense bone like structures in the defect area at
8 weeks (Fig. 3E and F). Quantification of new bone formation in the
defects showed a significantly higher volume percent (%) of radiopaque
structure in ad-BMP2 (43.37± 3.55% defect closure), compared with
the ad-BMP2+VEGFA (27.86± 2.89% defect closure) and other
controls (Fig. 3L). At 2 weeks, formation of the bone like structures was
relatively lower in all of the experimental groups, with ad-BMP2 group
demonstrating the highest amount of bony structures (Fig. 3K).
To confirm the formation of bony structures disclosed by microCT,
histological examination of H & E/Masson's trichrome stained sections
Fig. 3. Expression of BMP2 alone was superior to the combined delivery of BMP2 and VEGFA in formation of radiopaque bone like structures in a critical-sized rat
calvarial defect.
Illustration of the location of scaffold implantation sites in rat calvaria and implantation of scaffolds seeded with ad-BMP2, ad-BMP2+VEGFA, ad-GFP or un-
transduced rBMSC in rat calvarial bone defects (A and B). At 8 weeks, microCT examination of calvarial defects in the control groups showed few radiopaque bone-
like structures (C and D). In contrast, in ad-BMP2 and ad-BMP2+VEGFA scaffold explants at 8 weeks, abundant radiopaque bone-like areas were observed inside the
defect (E and F). Quantification of radiopaque bone like structures in the defects at 2 weeks (K) demonstrated a slightly higher amount of bone formation in ad-BMP2
group, whereas at 8 weeks (L) significantly more bone-like structures were found in ad-BMP2 than in the untransduced, ad-GFP or in the ad-BMP2+VEGFA group.
ANOVA test with Bonferroni post hoc analysis was performed for statistical analysis in (K and L). The error bars represent SEM. ***, p<0.000; **, p=0.001 to
0.01;*, p=0.01 to 0.05; ns, non-significant.
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was subsequently undertaken. Similar to the microCT findings, very few
bony structures were detected in all replicates of untransduced and ad-
GFP groups at both 2 and 8weeks (Fig. 4A, B, E and F). However,
formation of bony structures (black arrows) was detected at the junc-
tion of the defect, as well as inside the defects in all replicates in ad-
BMP2 and ad-BMP2+VEGFA groups at 2 weeks (Fig. 4C and D). At
8 weeks, formation of bony structures (blue-green stained areas with
black arrows) was more extensive with bony trabeculae extending
throughout the whole thickness of the defects (Fig. 4G and H). Bony
structure consisted of numerous osteocyte like cells both at 2 (black
arrowheads, inset C and D) and 8 (H & E staining not shown for
8 weeks) weeks. Occasional inflammatory and multinucleated giant
Fig. 4. Expression of BMP2 alone was superior to the combined delivery of BMP2 and VEGFA in formation of vital bony structures in a critical-sized rat calvarial
defect.
(A–H) Representative images of H & E/Masson's trichrome stained FFPE sections of scaffold explants from different experimental groups. Apart from the borders of
the calvarial defects, formation of bony structures was not obvious in the untransduced and ad-GFP groups both at 2 (A and B, H & E stained slides) and at 8 weeks (E
and F, Masson's trichrome stained slides). In both ad-BMP2 (C) and ad-BMP2+VEGFA (D) groups, formation of bony structures (black arrows) at the borders of the
defect (black dotted lines), peripherally and within the scaffold explants was observed as early as 2 weeks. Extensive bone formation (black arrows) with bony
trabeculae extending throughout the thickness of the scaffolds was found at 8 weeks in ad-BMP2 (G) and ad-BMP2+VEGFA (H) groups. Examination of the bony
structure at 2 weeks revealed numerous osteocyte-like cells (black arrowheads, inset C and D).
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cells were seen in all groups. In parallel with the in vitro molecular
findings and microCT observations, the amount of bone like structure in
ad-BMP2+VEGFA group was lower as compared to that of ad-BMP2
group as observed by H & E/Masson's trichrome analyses (Fig. 4C, D, G
and H).
3.4. De novo bone formation in ad-BMP2 and ad-BMP2+VEGFA rat
calvarial explants was associated increased angiogenesis
The association between enhanced bone formation and the degree
of angiogenesis in ad-BMP2 and ad-BMP2+VEGFA scaffold explants
was next examined by counting the blood capillaries/vessels in
Masson's trichrome stained slides at 8 weeks. Analyses of the scanned
Fig. 5. Adenoviral vector mediated delivery of BMP2 alone or in combination with VEGFA induced formation of capillary like structures in a critical sized rat
calvarial bone defect.
(A–D) Representative images of Masson's trichrome stained slides at 8 weeks showing higher numbers of blood capillaries/vessels in ad-BMP2 and ad-
BMP2+VEGFA explants than in the untransduced and ad-GFP explants. Black arrows indicate the pink/red stained capillaries/blood vessels containing brown/
orange stained erythrocytes (inset D, arrowheads indicating erythrocytes). (E) Quantification of blood capillaries/vessels demonstrated approximately twice the
number in ad-BMP2 and ad-BMP2+VEGFA, compared with the untransduced and ad-GFP explants. However, no significant difference in the number of blood
capillaries/vessels was found between the ad-BMP2 and ad-BMP2+VEGFA groups. ANOVA test with Bonferroni post hoc analysis was performed for statistical
analysis in (E). Error bars represent SEM. **, p=0.001 to 0.01;*, p=0.01 to 0.05; ns, non-significant.
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slides showed significantly higher numbers of blood capillaries/vessels
in ad-BMP2 and ad-BMP2+VEGFA rat BMSC explants, compared with
the ad-GFP and untransduced controls (Fig. 5A–E). The number of
blood capillaries/vessels in ad-BMP2+VEGFA was slightly but insig-
nificantly higher than in the ad-BMP2 explants (Fig. 5C–E).
3.5. De novo bone formation in ad-BMP2 and ad-BMP2+VEGFA rat
calvarial explants was associated with up-regulation of osteogenic markers
TaqMan qRT-PCR was used to examine the differentially expressed
osteogenesis related genes in poly(LLA-co-CL) scaffold explants from rat
calvarial bone defects at 2 weeks. It was interesting to observe that a
higher level of human BMP2mRNA from the implanted rat BMSC could
still be detected by 2weeks in the ad-BMP2 and ad-BMP2+VEGFA
scaffold explants (Fig. 6A). Nevertheless, the human BMP2 mRNA level
was much higher in ad-BMP2 compared to the ad-BMP2+VEGFA
scaffold explant (Fig. 6A). However, no human VEGFA mRNA could be
detected by 2weeks (data not shown). Osteogenesis related genes such
as rat Alpl and Runx2 were found to be up-regulated both in ad-BMP2
and ad-BMP2+VEGFA, compared with the ad-GFP and untransduced
BMSC scaffold explants (Fig. 6B and C).
Fig. 6. Delivery of BMP2 alone and in combination with VEGFA was associated with up-regulation of osteogenic markers in the in vivo scaffold explants.
ANOVA analysis demonstrated up-regulation of human BMP2 and osteogenesis related rat genes such as Alpl and Runx2 in the ad-BMP2 and ad-BMP2+VEGFA
scaffold explants, compared with the ad-GFP and untransduced explants (A–C). (D–H) Expression levels of innate immunity response genes (Ifna1, Ifnb1, Il1a and
Il1b) and osteoclast activating factor 1 (Ostf1) were similar in the ad-GFP, ad-BMP2 and ad-BMP2+VEGFA, compared to the untransduced explants. ANOVA test
with Bonferroni post hoc analysis was performed for statistical analysis. **p=0.001–0.01, **p=0.01–0.05, ns= non-significant.
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3.6. Adenoviral delivery of BMP2 alone and in combination with VEGFA
was not associated with adverse innate host response in the rat calvarial
defect
TaqMan qRT-PCR was used to examine the expression of genes
(Ifna1, Ifnb1, Il1a and Il1b) related to the innate response to adenoviral
infection in the scaffold explants from rat calvarial bone defects at
2 weeks. mRNA expression levels of these genes were similar in ad-GFP,
ad-BMP2 and ad-BMP2+VEGFA explants, compared with the un-
transduced BMSC explants (Fig. 6D–G). Likewise, mRNA expression of
the Ostf1 (osteoclast stimulating factor 1) was similar in all of the ex-
perimental groups (Fig. 6H).
4. Discussion
The critical-sized bone defect model is one of the most extensively
applied models for testing the osteogenic potential of growth factors
and/or scaffold material using mesenchymal stem cells (Gomes and
Fernandes, 2011). The current study tested the effectiveness of adeno-
viral mediated delivery of human BMP2 alone or in combination with
VEGFA in rBMSC, seeded onto a poly(LLA-co-CL) scaffolds in bone re-
generation. The results showed that the combined delivery of BMP2 and
VEGFA did not offer any additional advantage over BMP2 alone in
healing the rat calvarial bone defect.
In the current study, the adenoviral mediated delivery of BMP2 and
VEGFA was successful (Fig. 1). The increased mRNA expression levels
of BMP2 and VEGFA (both human and rat) in rBMSC were associated
with the induction of osteogenic marker genes (such as Alpl and Runx2)
and ALP protein in rBMSC seeded onto poly(LLA-co-CL) scaffolds at
both 3 and 14 days (Fig. 2A–G). Nevertheless, the expression levels of
Alpl and Runx2 were moderately but significantly lower in the com-
bined delivery group than in the ad-BMP2 group (Fig. 2A–D). In par-
allel, the in vitro calcium deposition as demonstrated by Alizarin red
staining in monolayer and in poly(LLA-co-CL) scaffold was lower in ad-
BMP2+VEGFA group (Fig. 2H). These results indicate that delivery of
BMP2 alone or in combination with VEGFA was able to differentiate
rBMSC seeded onto scaffolds towards an osteogenic pathway, however,
the ability of the combined delivery of BMP2 and VEGFA was inferior as
compared to the delivery of BMP2 alone. In parallel to these in vitro
observations, significantly more radiopaque bony structures were de-
tected at 8 weeks in the calvarial bone defects with ad-BMP2, compared
with the ad-BMP2+VEGFA, untransduced and ad-GFP groups (Fig. 3).
These observations corroborated with the histological findings of the H
& E/Masson's trichrome stained sections, showing formation of more
bony structures in the calvarial defects in the ad-BMP2 group, at both 2-
and 8weeks (Fig. 4).
In contrast to these findings, some previous studies have reported an
additive effect of the combined delivery of BMP2 and VEGFA (a low
ratio of VEGFA to BMP2 as in the current study) on bone formation over
the delivery of BMP2 alone (Peng et al., 2005; Zhang et al., 2011). The
added benefit of combining VEGFA with BMP2 has been attributed
mainly to the indirect effect of VEGFA enhancing angiogenesis and to a
lesser extent to the direct effect on osteoblasts (Kempen et al., 2009;
Street et al., 2002). In the current study, the reduced bone formation
ability of ad-BMP2+VEGFA was indeed contrary to a slightly higher
(but statistically insignificant) number of blood capillaries found in the
defect area, compared with the ad-BMP2 group (Fig. 5E). This indicates
that the enhanced angiogenesis as observed in ad-BMP2+VEGFA
group was not able to complement the osteogenic ability of BMP2
alone. It may be argued that the reduced bone formation in ad-
BMP2+VEGFA could be due to the slightly lower amount of ad-BMP2
virus particles used (80 MOI as compared with the 100 MOI used in the
ad-BMP2 group) in the combined delivery group. A dose dependent
reduction in new bone formation (a reduction of almost 50% bone
volume with 50% reduction in rhBMP2 amount) has been reported
previously for recombinant BMP2 in a rat calvarial bone defect model
(Young et al., 2009). Nevertheless, a higher degree of reduction in bone
formation (27.86% BV/TV bone formation for ad-BMP2+VEGFA
versus 43.37% for ad-BMP2) in the combined group cannot be solely
attributed to 20% reduction in the amount of ad-BMP2 virus particles.
This indicates that other mechanisms might also have contributed to
the reduced bone formation in the combined group. Inclusion of 1:4
ratio of ad-GFP and ad-BMP2 as an additional control might have been
helpful to clarify this issue.
Schönmeyr B et al. have demonstrated that the adenoviral medi-
cated delivery of VEGFA was able to inhibit significantly the expression
BMP2 when VEGFA and BMP2 were co-expressed, or uni-transfected rat
BMSC cells were co-cultured (Schönmeyr et al., 2009). This could be the
more likely explanation for reduced ability of the ad-BMP2+VEGFA
group because similar methods were used in the current study. Other
possible explanations could be the inhibition of BMP2 mediated os-
teoblastic differentiation by VEGFA (Lin et al., 2014) (Song et al.,
2011), dilution of the number of stem cells available for osteogenic
differentiation by favoring their differentiation towards the endothelial
lineage (Peng et al., 2002), or inhibition of endothelial to mesenchymal
transition (Hu et al., 2017). Additionally, VEGFA has been shown to
promote osteoclast recruitment in the osteogenic grafts, thereby in-
directly leading to bone resorption and reduced bone volume (Helmrich
et al., 2013). In the current study, this possibility is less likely as the
expression of Ostf1 (osteoclast stimulating factor 1) was similar both in
the combined delivery group and ad-BMP2 group.
Peng H et al. have reported that VEGFA was able to enhance cellular
survival at the bone regeneration site when combined with BMP4 (Peng
et al., 2002). However, the ability of VEGFA to support cell survival
appears to be dependent on cell type. In fact it has been reported that
adenoviral mediated co-expression of VEGFA and BMP4 resulted in
reduced proliferative ability of C2C12 cells compared with the ex-
pression of BMP4 alone (Li et al., 2009). It was interesting to note that
by 2 weeks, no human VEGFA mRNA was detected in the scaffold im-
plants at the defect site in all of the groups (data not shown), although
higher expression of human BMP2 was found in the ad-BMP2 group
(Fig. 6A). This could be due to the selective cell death or differentiation
of rBMSC co-expressing BMP2 and VEGFA at the defect site and war-
rants further investigation.
In conclusion, the current study tested the feasibility of a recently
established model system (poly(LLA-co-CL) scaffold+BMSC trans-
duced with adenoviral particles) (Sharma et al., 2016; Sharma et al.,
2018) for bone regeneration using a more clinically relevant critical
sized rat calvarial bone defect model and demonstrated that the de-
livery of BMP2 alone or in combination with VEGFA was not associated
with adverse host response. More importantly, the delivery of BMP2
alone was more efficient as compared to the combined delivery of
BMP2 and VEGFA in bone regeneration. However, the positive effects of
VEGFA on angiogenesis cannot be denied and it highlights the im-
portance of selecting appropriate growth factors and correct formula-
tion strategies for successful bone regeneration in the model system
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